公开(公告)号：US20240327334A1

公开(公告)日：2024-10-03

申请号：US18390287

申请日：2023-12-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri GAO ,  Bin WANG ,  Hui CAO ,  Jiajun ZHANG ,  Yuk Ming SIU ,  Jiang LONG ,  Wei LI ,  Matthew C. RHODES ,  Xuechao XING ,  Jianming YU ,  Scott MITCHELL ,  Yat Sun OR

IPC: C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/40

CPC classification number: C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/4015

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20250059174A1

公开(公告)日：2025-02-20

申请号：US18797882

申请日：2024-08-08

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jiajun ZHANG ,  Yuk Ming SIU ,  Peilin XU ,  Matthew C. RHODES ,  Hui CAO ,  Yat Sun OR ,  Xuri GAO ,  Wei LI ,  Xuechao XING ,  Scott MITCHELL

IPC: C07D413/14 ,  A61K31/4245 ,  A61K31/429 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/541 ,  A61K31/553 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFRα, PDGFRβ) kinases.

公开(公告)号：US20250042898A1

公开(公告)日：2025-02-06

申请号：US18782372

申请日：2024-07-24

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yuk Ming SIU ,  Jiajun ZHANG ,  Matthew C. RHODES ,  Peilin XU ,  Hui CAO ,  Scott MITCHELL ,  Yat Sun OR

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D519/00

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFRα, PDGFRβ) kinases.

公开(公告)号：US20240368096A1

公开(公告)日：2024-11-07

申请号：US18582877

申请日：2024-02-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Samuel BARTLETT ,  Joseph D. PANARESE ,  Sourav GHORAI ,  Nathaniel Thomas KENTON ,  Sean RAFFERTY ,  Jonathan THIELMAN ,  Peilin XU ,  Bin WANG ,  William CASSELS ,  Scott MITCHELL ,  Yat Sun OR

IPC: C07D285/36 ,  C07D417/04 ,  C07D417/12 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240368174A1

公开(公告)日：2024-11-07

申请号：US18627591

申请日：2024-04-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam SZYMANIAK ,  Robert LEON ,  Kevin McGRATH ,  Xiben LI ,  Tyler J. MANN ,  Jianming YU ,  In Jong KIM ,  Scott MITCHELL ,  Yat Sun OR

IPC: C07D491/048 ,  A61K31/4375 ,  A61K45/06 ,  A61P31/14 ,  C07B59/00 ,  C07D519/00

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240325409A1

公开(公告)日：2024-10-03

申请号：US18587048

申请日：2024-02-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Sean RAFFERTY ,  Sourav GHORAI ,  Nathaniel Thomas KENTON ,  Peilin XU ,  Samuel BARTLETT ,  Scott MITCHELL ,  Joseph D. PANARESE ,  Yat Sun OR

IPC: A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

CPC classification number: A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.